DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment Meeting Abstract
| Authors: | Lee, H. C.; Cohen, A. D.; Chari, A.; Hultcrantz, M.; Nooka, A. K.; Callander, N. S.; Suvannasankha, A.; Badros, A.; Libby, E. N.; Trudel, S.; Richardson, P. G.; Sborov, D. W.; Otero, P. R.; Lonial, S.; Zhi, E.; Lewis, E.; Gupta, I.; Opalinska, J. |
| Abstract Title: | DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment |
| Meeting Title: | 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2020 May 29-31 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-05-20 |
| Start Page: | 439s |
| Language: | English |
| ACCESSION: | WOS:000560368303304 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.15_suppl.8519 |
| Notes: | Meeting Abstract: 8519 -- Source: Wos |
